A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

NCT03825705 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Interventions

DRUG: TQB2450 injection
DRUG: Anlotinib

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.